Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue SarcomasJennifer L. Anderson, Noah Federman|PLoS ONE|2015Cited by 39
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing SarcomaPaul A. Meyers, Joseph A. Ludwig, Lara E. Davis et al.|Journal of Clinical Oncology|2024Cited by 36
[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trialGiulia Polverari, Noah Federman, Francesco Ceci et al.|EJNMMI Research|2020Cited by 15